Published in Curr Opin Cardiol on May 01, 2010
Arrhythmogenic right ventricular dysplasia back in force. Am J Cardiol (2014) 2.12
The connexin43 carboxyl terminus and cardiac gap junction organization. Biochim Biophys Acta (2011) 1.05
Mechanotransduction in cardiac hypertrophy and failure. Circ Res (2015) 1.01
Mutations with pathogenic potential in proteins located in or at the composite junctions of the intercalated disk connecting mammalian cardiomyocytes: a reference thesaurus for arrhythmogenic cardiomyopathies and for Naxos and Carvajal diseases. Cell Tissue Res (2012) 0.88
Novel missense mutations in exon 15 of desmoglein-2: role of the intracellular cadherin segment in arrhythmogenic right ventricular cardiomyopathy? Heart Rhythm (2010) 0.87
Barth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies. Front Genet (2016) 0.80
Genetics and Genomics of Single-Gene Cardiovascular Diseases: Common Hereditary Cardiomyopathies as Prototypes of Single-Gene Disorders. J Am Coll Cardiol (2016) 0.79
Stop-gain mutations in PKP2 are associated with a later age of onset of arrhythmogenic right ventricular cardiomyopathy. PLoS One (2014) 0.77
Knockdown of Plakophilin 2 Downregulates miR-184 Through CpG Hypermethylation and Suppression of the E2F1 Pathway and Leads to Enhanced Adipogenesis In Vitro. Circ Res (2016) 0.75
Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm. Nat Commun (2017) 0.75
Inhibition of adipogenesis by Wnt signaling. Science (2000) 9.72
Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA (1996) 7.03
Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation (2001) 5.68
Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med (1988) 5.22
A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med (2009) 4.54
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. Cell (2003) 4.38
Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res (2005) 3.99
Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet (2004) 3.88
Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation (2006) 3.44
Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Med (1990) 3.41
Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet (2000) 3.39
Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest (2006) 3.22
Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet (2001) 3.12
Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation (2005) 3.11
Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature (2004) 3.03
The heart in human dystrophinopathies. Cardiology (2003) 2.97
Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet (2008) 2.84
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation (2006) 2.81
Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? Circulation (1998) 2.58
Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation (2007) 2.56
Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation (2003) 2.56
Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet (2006) 2.26
Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol (2002) 2.22
Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation (2003) 2.13
Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol (2000) 1.93
A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. J Am Coll Cardiol (2003) 1.84
Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol (2009) 1.83
[Electrocardiology of 4 cases of right ventricular dysplasia inducing arrhythmia]. Arch Mal Coeur Vaiss (1978) 1.69
Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet (2006) 1.68
Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene (2004) 1.63
Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation (1992) 1.61
Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia: sensitivity, specificity, and observer variability of fat detection versus functional analysis of the right ventricle. J Am Coll Cardiol (2006) 1.55
Electrocardiographic pattern in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol (2009) 1.50
Sudden unexpected nontraumatic death in 54 young adults: a 30-year population-based study. Am J Cardiol (1995) 1.48
Canonical Wnt signaling functions in second heart field to promote right ventricular growth. Proc Natl Acad Sci U S A (2007) 1.46
Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res (2009) 1.28
Membrane-anchored plakoglobins have multiple mechanisms of action in Wnt signaling. Mol Biol Cell (1999) 1.13
Missense mutations in desmocollin-2 N-terminus, associated with arrhythmogenic right ventricular cardiomyopathy, affect intracellular localization of desmocollin-2 in vitro. BMC Med Genet (2007) 1.11
Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm (2009) 0.98
Arrhythmogenic right ventricular disease: MR imaging vs angiography. AJR Am J Roentgenol (1993) 0.98
Electrocardiographic findings over time in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Cardiol (2005) 0.81
Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest (2006) 3.22
Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet (2009) 2.50
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol (2005) 2.42
Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res (2012) 2.25
Surprises of the genome and "personalized" medicine. J Am Coll Cardiol (2008) 1.84
Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A (2003) 1.74
Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res (2007) 1.51
Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. Eur J Clin Invest (2010) 1.47
Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res (2008) 1.33
Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation (2009) 1.30
Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res (2009) 1.28
Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet (2007) 1.23
The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord (2009) 1.18
Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Natl Acad Sci U S A (2005) 1.09
Nature's genetic gradients and the clinical phenotype. Circ Cardiovasc Genet (2009) 1.04
Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur J Clin Invest (2010) 0.97
Molecular genetic and functional characterization implicate muscle-restricted coiled-coil gene (MURC) as a causal gene for familial dilated cardiomyopathy. Circ Cardiovasc Genet (2011) 0.93
Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity. Cardiovasc Res (2012) 0.90
Phenotypic plasticity of sarcomeric protein mutations. J Am Coll Cardiol (2007) 0.89
Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. Am J Physiol Heart Circ Physiol (2013) 0.86
Can an energy-deficient heart grow bigger and stronger? J Am Coll Cardiol (2003) 0.80
Noncoding RNAs in cardiovascular biology and disease. Circ Res (2013) 0.77
FAT10 protects cardiac myocytes against apoptosis. J Mol Cell Cardiol (2013) 0.77
DNA sequence variants and the practice of medicine. Curr Opin Cardiol (2010) 0.76
Determinants of plasma vitamin D levels in patients with acute coronary syndromes. Eur J Clin Invest (2011) 0.76
Clinical significance of single nucleotide polymorphisms in PCSK9. Curr Atheroscler Rep (2007) 0.75
Genome-wide association study of susceptibility alleles for coronary artery disease. Curr Atheroscler Rep (2008) 0.75
A novel genetic risk factor for myocardial infarction. Curr Atheroscler Rep (2007) 0.75
Ali J. Marian: life and science are one. Circ Res (2014) 0.75
Cholesteryl ester transfer protein TaqIB polymorphism in the cholesterol and recurrent events study. Curr Atheroscler Rep (2005) 0.75
Errors in DNA replication and genetic diseases. Curr Opin Cardiol (2013) 0.75
Interleukin-18 and cardiovascular events. Curr Atheroscler Rep (2006) 0.75
Matrix metalloproteinase-I gene variants and risk of myocardial infarction. Curr Atheroscler Rep (2006) 0.75
Pharmacogenetic study of statin therapy and cholesterol reduction. Curr Atheroscler Rep (2005) 0.75